Synergistic Interactions between Heregulin and Peroxisome Proliferator-activated Receptor-γ (PPARγ) Agonist in Breast Cancer Cells

被引:13
|
作者
Park, Bae-Hang [2 ]
Lee, Sean-Bong [3 ]
Stolz, Donna B. [4 ]
Lee, Yong J. [5 ]
Lee, Byeong-Chel [1 ,2 ]
机构
[1] Univ Pittsburgh, Sch Med, Hillman Canc Ctr, Univ Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol & Oncol, Pittsburgh, PA 15213 USA
[3] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA
[4] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA
[5] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA
基金
美国国家卫生研究院;
关键词
LIGAND TROGLITAZONE; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; CARCINOMA CELLS; TUMOR-CELLS; DNA-DAMAGE; PHASE-II; IN-VIVO; AUTOPHAGY; GROWTH;
D O I
10.1074/jbc.M110.191718
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Here, we demonstrate that troglitazone (Rezulin), a peroxisome proliferator-activated receptor agonist, acted in synergy with heregulin to induce massive cell death in breast cancer cells. Although the combination of heregulin and troglitazone (HRG/TGZ) induced both apoptosis and necrosis, the main mode of cell death was caspase-independent and occurred via necrosis. This combination increased generation of superoxide in mitochondria, which in turn destabilized mitochondria potential. Pretreatment with N-acetyl-L-cysteine and catalase expression ameliorated cell death induced by the combination treatment, indicating a role of oxidative stress in mediating HRG/TGZ-induced cell death. Notably, pretreatment with pyruvate significantly prevented the cell death, suggesting a potential mechanistic link between metabolic stress and HRG/TGZ-induced cell death. The activation of the HRG signaling axis has been considered as a poor prognostic factor in breast cancer and confers resistance to gefitinib (Iressa) and tamoxifen. However, our data presented here paradoxically suggest that HRG expression can actually be beneficial when it comes to treating breast cancer with peroxisome proliferator-activated receptor-gamma ligands. Taken together, the combination of HRG and TGZ may provide a basis for the development of a novel strategy in the treatment of apoptosis-resistant and/or hormone-refractory breast cancer.
引用
下载
收藏
页码:20087 / 20099
页数:13
相关论文
共 50 条
  • [31] A SPECIFIC PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)-δ AGONIST ATTENUATES LIVER FIBROGENESIS
    Iwaisako, Keiko
    Taura, Kojiro
    Paik, Yonghan
    Brenner, David A.
    Schnabl, Bernd
    HEPATOLOGY, 2009, 50 (04) : 405A - 406A
  • [32] Synergy Between Peroxisome Proliferator-Activated Receptor γ Agonist and Radiation Therapy in Cancer
    Huang, G.
    Sun, X.
    Li, M.
    Yin, L.
    Lu, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S116 - S117
  • [33] Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
    Agrawal, R.
    Jain, P.
    Dikshit, S. N.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (02) : 87 - 97
  • [34] A natural propenoic acid derivative activates peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)
    Genovese, Salvatore
    Foreman, Jennifer E.
    Borland, Michael G.
    Epifano, Francesco
    Gonzalez, Frank J.
    Curini, Massimo
    Peters, Jeffrey M.
    LIFE SCIENCES, 2010, 86 (13-14) : 493 - 498
  • [35] Unraveling the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) expression in colon carcinogenesis
    Peters, Jeffrey M.
    Walter, Vonn
    Patterson, Andrew D.
    Gonzalez, Frank J.
    NPJ PRECISION ONCOLOGY, 2019, 3 (1)
  • [36] Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist
    Ninomiya, Hiroyo
    Hirata, Ayumu
    Kozawa, Junji
    Nakata, Shinsuke
    Kimura, Takekazu
    Kitamura, Tetsuhiro
    Yasuda, Tetsuyuki
    Otsuki, Michio
    Imagawa, Akihisa
    Kaneto, Hideaki
    Funahashi, Tohru
    Shimomura, Iichiro
    INTERNAL MEDICINE, 2016, 55 (09) : 1143 - 1147
  • [37] Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells
    Nicholas, SB
    Kawano, Y
    Wakino, S
    Collins, AR
    Hsueh, WA
    HYPERTENSION, 2001, 37 (02) : 722 - 727
  • [38] Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ
    Narala, Venkata R.
    Smith, Monica R.
    Adapala, Ravi K.
    Ranga, Rajesh
    Panati, Kalpana
    Moore, Bethany B.
    Leff, Todd
    Reddy, Vudem D.
    Kondapi, Anand K.
    Reddy, Raju C.
    GENE THERAPY AND MOLECULAR BIOLOGY, 2009, 13 (01): : 20 - 25
  • [39] Peroxisome proliferator-activated receptor-α -: Friend or foe?
    Yagil, Chana
    Yagil, Yoram
    HYPERTENSION, 2007, 50 (05) : 847 - 850
  • [40] Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer
    Chandran, Karthic
    Goswami, Sudeshna
    Sharma-Walia, Neelam
    ONCOTARGET, 2016, 7 (13) : 15577 - 15599